每经AI快讯，8月12日，CRO指数盘中显著回调，现跌2.21%。成分股普遍走弱，成都先导跌4.14%、金 凯生科跌3.84%、阳光诺和跌3.82%、益诺思跌3.31%、奥浦迈跌2.86%领跌。 （文章来源：每日经济新闻） ...

Group 1 - The company plans to acquire 100% equity of Pengli Biopharmaceutical Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment [1][2] - The company has received an inquiry letter from the Shanghai Stock Exchange regarding the asset acquisition and fundraising, which requires a response within one month [2] - Due to the complexity of the issues raised in the inquiry letter, the company has applied for a one-month extension to submit its response [2][3] Group 2 - The completion of the transaction is subject to multiple conditions, including approval from the Shanghai Stock Exchange and registration consent from the China Securities Regulatory Commission [2] - The company commits to timely information disclosure in accordance with relevant laws and regulations as the transaction progresses [3]

上海奥浦迈生物科技股份有限公司（以下简称"公司"）拟通过发行股份及 支付现金方式购买澎立生物医药技术（上海）股份有限公司 100.00%股权（以下 简称"本次发行股份及支付现金购买资产"），并向不超过 35 名特定投资者发行 股票募集配套资金（以下简称"本次募集配套资金"，与本次发行股份及支付现 金购买资产合称"本次交易"）。 公司于 2025 年 7 月 10 日收到上海证券交易所（以下简称"上交所"）出具 的《关于上海奥浦迈生物科技股份有限公司发行股份及支付现金购买资产并募集 配套资金的审核问询函》（上证科审（并购重组）〔2025〕24 号）（以下简称"《审 核问询函》"）。根据《审核问询函》的要求，公司回复审核问询的时间总计不得 超过 1 个月。如难以在前述时间内回复的，可以按照《上海证券交易所上市公司 重大资产重组审核规则》的规定，向上交所申请延期一次，时间不得超过 1 个月。 证券代码：688293 证券简称：奥浦迈 公告编号：2025-059 上海奥浦迈生物科技股份有限公司 关于延期回复《关于上海奥浦迈生物科技股份有限公 司发行股份及支付现金购买资产并募集配套资金的 审核问询函》的公告 本公司董事 ...

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 当视角进一步聚焦至中国经济中心上海时，该地区的医药生物行业CFO薪酬溢价效应更为明显。统计范 围内的39家上海医药生物企业，CFO薪酬总额达4442.62万元，其平均年薪跃升至约113.91万元（中位数 102.20万元）。 这一数字相比全市场CFO平均薪酬高出39.8%（约32.43万元），凸显了上海作为高运营成本、高人才竞 争核心区域，叠加医药生物这一高附加值行业的强力薪酬溢价。 在上海地区医药生物行业上市公司CFO薪酬榜单中，奥浦迈（股票代码：688293.SH）的首席财务官倪 亮萍女士以140.29万元的年薪位列第九位。其2023年年薪为141.60万元，2024年略有下降，变化额 为-1.31万元，变化率为-0.93%。 倪亮萍女士在财务管理领域拥有丰富经验。公开资料显示，倪亮萍出生于1984年，毕业于上海财经大 学，目前为中欧国际商学院EMBA在读。她持有英国皇家特许管理会计师证书（CIMA）和全球特许管 理会计师证书（CGMA）。 在加入奥浦迈之前，倪亮萍女士的职业履历主要包括：2008年至2018年间历 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688180 | 君实生物 | 39.46 | 4.78% | 19.60万 | 7.55 Z | | 688185 | 康希诺 | 83.37 | 4.21% | 6.30万 | 5.27亿 | | 688293 | 奥浦迈 | 59.34 | 4.11% | ● 1.86万 | 1.10亿 | | 300142 | 沃森生物 | 13.59 | 3.82% | 120.51万 | 16.64亿 | | 000518 | *ST四环 | 2.32 | 2.20% | 12.03万 | 2773.23万 | | 688331 | 荣昌生物 | 63.70 | 1.84% | 7.96万 | 5.03亿 | | 002581 | ST未名 | 7.33 | 1.52% | 9.13万 | 6696.70万 | | 002773 | 康弘药业 | 42.06 | 1.50% | 10.14万 | 4.24亿 | | 300841 | 康华生物 | 78 ...

Group 1 - On August 1, the financing buy-in amount for Aopumai was 0.13 billion, ranking 985th in the two markets, with a financing repayment amount of 0.08 billion, resulting in a net buy of 4.4583 million [1] - Over the last three trading days, Aopumai received financing buy-ins of 0.12 billion, 0.15 billion, and 0.13 billion respectively [1] Group 2 - In terms of securities lending, there were no shares sold or net sold on that day [2]

证券之星消息，7月31日生物制品板块较上一交易日上涨0.05%，安科生物领涨。当日上证指数报收于 3573.21，下跌1.18%。深证成指报收于11009.77，下跌1.73%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300009 | 安科生物 | 12.11 | 20.02% | 330.56万 | | 38.34亿 | | 688136 | 科兴制药 | 53.25 | 13.15% | 19.24万 | | 9.56亿 | | 688278 | 特宝生物 | 91.33 | 7.46% | 12.10万 | | 11.04亿 | | 300841 | 康华生物 | 77.47 | 5.76% | 11.37万 | | 8.67亿 | | 688293 | 奥浦迈 | 60.50 | 5.38% | 2.60万 | | 1.58亿 | | 301393 | 吴帆生物 | 61.69 | 4.86% | 7.17万 | | 4.37亿 | ...

进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为1632.50万元。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报·数据宝统计显示，奥浦迈今日收盘价为58.96元，上涨4.59%，日换手率为3.81%，成交额为 1.73亿元，全天主力资金净流出1136.71万元，近5日该股累计上涨12.71%，近5日资金合计净流出 2954.91万元。 （文章来源：证券时报网） 两融数据显示，该股最新融资余额为9979.61万元，近5日增加278.41万元，增幅为2.87%。（数据宝） 7月29日奥浦迈大宗交易一览 奥浦迈7月29日大宗交易平台出现一笔成交，成交量10.00万股，成交金额583.70万元，大宗交易成交价 为58.37元，相对今日收盘价折价1.00%。该笔交易的买方营业部为华泰证券股份有限公司总部，卖方营 业部为中信建投证券股份有限公司深圳滨海大道证券营业部。 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | ...

| 2025-07-29 | 奥浦迈 | 688293 | 58.37 583.7 | 10 | 华泰证券股份有限 | 中信建投证券股份 I . | | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | 公司总部 | 卖出营业部 有限公司深圳滨海 | 7月29日，奥浦迈大宗交易成交10万股，成交额583.7万元，占当日总成交额的3.26%，成交价58.37元，较市场收盘价58.96元折价1%。 ...

Core Viewpoint - The company, Aopumai (688293), has shown significant growth in its financial performance for the first half of 2025, driven primarily by its cell culture media products, with a notable increase in revenue and net profit compared to the previous year [2][4]. Financial Performance - In the first half of 2025, the company achieved approximately 177 million in operating revenue, representing a year-on-year increase of about 23.25% [2] - The net profit attributable to shareholders was approximately 37 million, reflecting a year-on-year increase of about 53.28% [2] - The net profit after deducting non-recurring items was approximately 29 million, showing a year-on-year increase of about 73.46% [2] Product and Market Insights - The company's cell culture media products have experienced high-level growth both year-on-year and quarter-on-quarter, with the product business segment seeing over 50% growth in Q2 2025 [2] - The company is recognized as a leading domestic manufacturer in the mid-to-high-end protein antibody drug sector, with an increasing market share in the cell culture media industry [5] Customer and Business Development - The company has established itself as a qualified supplier for several foreign pharmaceutical companies, although the ramp-up of new overseas customers will take time to reflect in financial results [3] - As of the end of Q1 2025, the company has identified nine commercial projects utilizing its cell culture media products, with expectations for increased contributions to revenue as these projects progress [4] Asset Restructuring - The company is currently in the review phase of its asset restructuring process, having received acceptance notification from the Shanghai Stock Exchange at the end of June [7] Investment Ratings - Over the past 90 days, three institutions have issued buy ratings for the stock, indicating positive sentiment among analysts [8]